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Abstract
Background: The ten mouse and six human members of the Schlafen (Slfn) gene family all contain an AAA domain. Little is
known of their function, but previous studies suggest roles in immune cell development. In this report, we assessed Slfn
regulation and function in macrophages, which are key cellular regulators of innate immunity.
Methodology/Principal Findings: Multiple members of the Slfn family were up-regulated in mouse bone marrow-derived
macrophages (BMM) by the Toll-like Receptor (TLR)4 agonist lipopolysaccharide (LPS), the TLR3 agonist Poly(I:C), and in
disease-affected joints in the collagen-induced model of rheumatoid arthritis. Of these, the most inducible was Slfn4. TLR
agonists that signal exclusively through the MyD88 adaptor protein had more modest effects on Slfn4 mRNA levels, thus
implicating MyD88-independent signalling and autocrine interferon (IFN)-b in inducible expression. This was supported by
the substantial reduction in basal and LPS-induced Slfn4 mRNA expression in IFNAR-1
2/2 BMM. LPS causes growth arrest in
macrophages, and other Slfn family genes have been implicated in growth control. Slfn4 mRNA levels were repressed during
macrophage colony-stimulating factor (CSF-1)-mediated differentiation of bone marrow progenitors into BMM. To
determine the role of Slfn4 in vivo, we over-expressed the gene specifically in macrophages in mice using a csf1r promoter-
driven binary expression system. Transgenic over-expression of Slfn4 in myeloid cells did not alter macrophage colony
formation or proliferation in vitro. Monocyte numbers, as well as inflammatory macrophages recruited to the peritoneal
cavity, were reduced in transgenic mice that specifically over-expressed Slfn4, while macrophage numbers and
hematopoietic activity were increased in the livers and spleens.
Conclusions: Slfn4 mRNA levels were up-regulated during macrophage activation but down-regulated during
differentiation. Constitutive Slfn4 expression in the myeloid lineage in vivo perturbs myelopoiesis. We hypothesise that
the down-regulation of Slfn4 gene expression during macrophage differentiation is a necessary step in development of this
lineage.
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Introduction
Hematopoietic stem cells in the bone marrow have the potential
to self-renew or progress into various differentiation pathways to
give rise to all types of mature blood cells, a process known as
hematopoiesis [1]. Blood monocytes arise through a sequential
series of developmental steps in which hematopoietic stem cells
commit to common myeloid progenitors, followed by granulocyte-
macrophage progenitors, monoblasts and finally pro-monocytes
[2]. Macrophage proliferation and differentiation is controlled by
macrophage colony-stimulating factor (CSF-1) [3]. Interferons
(IFNs) also play an active role in this process as demonstrated by
the phenotype of IFN-b
2/2 mice, which have a reduction in
circulating macrophages and granulocytes because of defective
maturation of primitive bone marrow hematopoiesis [4]. This
study examines the possible role of an IFN-regulated gene family
in monocytopoiesis.
The Schlafen (Slfn) family [5,6] has been identified in every
mammalian genome, and in the genome of amphibians and the
chondrichthyan Callorhinchus milii (‘‘elephant fish’’) [7]. Ten murine
(m-) and six human (h-) Slfn members have been identified, of
which only two members (hSLFN5/mSlfn5;h SLFN14/mSlfn14) are
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15723one-to-one orthologs, consistent with rapid evolution of this family
across mammalian species. hSLFN12 and hSLFN12like have four
orthologs in mice (mSlfn1,m Slfn2,m Slfn3, and mSlfn4), whilst
hSLFN11 and hSLFN13 have three (mSlfn8,m Slfn9, and mSlfn10)
[7]. All Slfn proteins contain a single N-terminal divergent AAA
(ATP-ases associated with various cellular activities) domain,
which is presumed to be involved in GTP/ATP binding [5,6]. The
longer isoforms (Slfn5, Slfn8, Slfn9, Slfn10, and predicted Slfn14),
which represent a subgroup of the family, also contain weak but
significant homology to several motifs found in members of DNA/
RNA helicase superfamily I [6], suggesting involvement in DNA/
RNA metabolism and/or pathogen recognition.
The Slfn genes are predominantly expressed in cells of the
immune system and are differentially regulated during develop-
mental processes. During T-cell development, Slfn1 and Slfn2
mRNA expression increased and Slfn4 mRNA expression
decreased [5,8], whilst mRNA levels of Slfn3, Slfn5, Slfn8, Slfn9
and Slfn10 were unaltered [6]. More recently, Condamine et al.
reported that Slfn3 expression was elevated in CD4
+ CD25
+ T
regulatory cells as compared to CD4
+ CD25
2 T cells [9]. The Slfn
genes were also regulated during IL-6 or LIF-induced differenti-
ation of M1 monocytic leukaemia cells; the mRNA levels of all Slfn
genes, except Slfn3 and Slfn9 were up-regulated [6]. Conversely,
Slfn2 expression was down-regulated during the differentiation of
FDCP-1 cells into erythroid, monocytic, neutrophilic, megakar-
yocytic, basophilic, and eosinophilic cells [10].
In addition to regulation during cell development, Slfn gene
expression was also modulated during bacterial infections [6,11,12],
which suggests a role for this gene family in host defence. The first
non-redundant function of a Slfn family member was described
recently by Berger et al., who reported a loss of function Slfn2
mutation (dubbed elektra) that caused reduced numbers of T cells
and monocytes, and increased susceptibility to bacterial and viral
infections comparable to that seen with a mutation in Myd88, which
encodes an adaptor protein in the Toll-like Receptor (TLR)
pathway [13]. The monocyte defect was characterised by a
disproportionate loss of Ly6C
+ inflammatory monocytes [13],
implying that Slfn2 is required for the maturation and/or survival of
this monocyte sub-set. Katsoulidis et al. [14] have also implicated
Slfn2 in hematopoietic development; they reported that Slfn2
knockdown promoted mouse hemopoietic colony formation and
impaired the growth suppressive actions of IFN-a.
Gain-of-function studies also suggest a role for Slfn family
members in cell proliferation, development and differentiation.
For example, ectopic expression of Slfn1 or Slfn8 in all thymocyte
lineages in vivo perturbed thymocyte development [5,6], and Slfn1
has also been shown to cause cell cycle arrest in vitro by repressing
mitogen-inducible cyclin D1 expression [5,15]. Despite these
recent studies, very little is known about the specific molecular
functions of the Slfn family in macrophages. We therefore set out to
profile the regulated expression patterns of Slfn family members in
this lineage. In doing so, we showed that Slfn4 was strikingly
regulated during macrophage activation and differentiation.
Utilising a novel binary system for tissue-specific gene expression,
we also show that ectopic expression of Slfn4 in cells of the myeloid
lineage in vivo does not alter cell proliferation, but nevertheless
disrupts normal myelopoiesis.
Results
Up-regulation of Slfn mRNA expression in activated bone
marrow-derived macrophages (BMM)
We began our studies on Slfn expression and function in
macrophages by assessing the mRNA expression of those family
members that could easily be discriminated by quantitative real-
time PCR, in primary mouse BMM stimulated with the TLR4
agonist, LPS. Upon addition of LPS, Slfn1, Slfn2, and Slfn4 mRNA
levels were increased at all time points examined, with maximal
induction after 24 hours LPS treatment. Peak induction for Slfn5,
Slfn8, and Slfn9 was more rapid, with maximal up-regulation being
apparent at 4h post-LPS treatment (Figure 1A). These data
indicate distinct kinetics in regulation between members that do
(Slfn5, Slfn8, and Slfn9) or do not (Slfn1, Slfn2, and Slfn4) contain the
helicase homology region. The most strikingly regulated gene in
terms of fold response was Slfn4 (,200 fold). The induction of
multiple Slfn genes in primary macrophages detected by qRT-
PCR confirms comparative microarray data that we have placed
in the public domain [16] (see also biogps.gnf.org).
To confirm the relevance of the induction of Slfn genes in
macrophages to inflammatory processes, we examined gene
Figure 1. Induction of Slfn expression by LPS in BMM, and in
the CIA mouse model. (A) BMM were stimulated with LPS over a time
course (0h no treatment control, 2h, 4h, 8h, 24h), RNA was extracted
and reverse transcribed, and the expression of Slfn1, Slfn2, Slfn4, Slfn5,
Slfn8, and Slfn9 was determined using quantitative real-time PCR. Data
(mean + SEM) are combined from 3 independent experiments. * P,0.05
compared to control; ** P,0.01 compared to control; *** P,0.001
compared to control. (B) RNA from whole joints (disease affected, score
3; or unaffected, score 0) from mice with CIA was used to synthesise
cDNA. mRNA expression of Slfn1, Slfn2, Slfn4, Slfn5, Slfn8, Slfn9, csf1r, and
Emr1 was determined using real-time PCR. The data, displayed as fold
induction relative to control (score 0), are combined from two
independent experiments (mean + range).
doi:10.1371/journal.pone.0015723.g001
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the mouse collagen-induced arthritis (CIA) model of rheumatoid
arthritis (Figure 1B). The expression of the macrophage genes
Emr1 (F4/80) and csf1r was increased in CIA-affected joints,
consistent with the association between macrophage infiltration
and joint destruction and disease progression [17]. In this model,
mRNA levels of Slfn family members that do not contain a helicase
homology domain (Slfn1, Slfn2, Slfn4) were all elevated, with Slfn4
mRNA expression increased ,8 fold compared to joints that were
not disease-affected (Figure 1B). Hence, Slfn4 mRNA levels were
strongly up-regulated in both in vitro (Figure 1A) and in vivo
(Figure 1B) inflammation models.
Promoter analysis of the murine Slfn4 locus
Genome scale analysis of promoter usage by cap analysis of
gene expression (CAGE) has mapped the large majority of mouse
transcription start sites (TSS) [18]. Amongst the many cell types
analysed were BMM treated with LPS. Figure 2 shows a schematic
representation of the Slfn4 major TSS and proximal promoter
region as defined by CAGE analysis (the primary FANTOM 3
CAGE data can be accessed through fantom3.gsc.riken.jp). The
TSS starts on the expected pyrimidine/purine initiator [18], and
lies downstream of a TATA box. Scanning of the promoter region
with JASPAR (jaspar.cgb.ki.se) reveals sites that conform to the
position weight matrix for AP1 and PU.1 and two copies of IFN-
responsive elements, STAT1 and IRF1. These sequences suggest
that Slfn4 is a likely target of IFN-dependent signaling pathways
downstream of TLRs [19].
TLR agonists up-regulate Slfn4 mRNA via the autocrine
action of type I IFN
In macrophages, TLR4 and TLR3 ligands utilize MyD88-
independent signalling to induce the type I IFN, IFN-b, which then
acts as an autocrine factor. IFN-b is not produced in this cell type in
response to TLR ligands that exclusively use the MyD88 adaptor
protein. To test the prediction from the promoter analysis that Slfn4
is a target of autocrine type I IFN, we examined Slfn4 mRNA
regulation in BMM stimulated with a variety of TLR agonists. We
also examined the effects of IFN-c, a pro-inflammatory cytokine
that synergizes with TLR agonists in macrophage activation [20],
since this cytokine has been reported to regulate mRNA stability via
MyD88 [21]. As shown in Figure 3A, each of the different TLR
agonists up-regulated the expression of Slfn4 mRNA, but the
magnitude of the response differed greatly. Agonists of TLR4 (LPS)
and TLR3 (poly(I:C)) caused the highest induction of Slfn4 mRNA
expression (.200 fold and .2000 fold respectively) compared to
the up-regulation by other TLR agonists or IFN-c (5–25 fold).
TLR3- and TLR4-mediated activation of TRIF in a MyD88-
independent fashionpromotes transcription of IFN-b, which in turn
act in an autocrine fashion via the type 1 IFN receptor (IFNAR) to
induce the expression of downstream target genes [19]. To confirm
the intermediate role of IFN, we examined IFNAR-1 null mice.
Interestingly, the mutant mice expressed lower basal levels of Slfn4
in BMM. Whereas LPS strongly up-regulated Slfn4 mRNA
expression in BMM from wild-type mice (,300 fold), this response
was dramatically reduced in IFNAR-1
2/2 BMM (,20 fold,
Figure 3B). These findings confirm that Slfn4 is a type I IFN target
gene, but indicate also that it contains some IFN-independent
responsive elements. It is possible that the perfect AP1 site
highlighted in Figure 2 contributes to type I IFN-independent
responses.
The Slfn gene families of mouse and human, like other IFN-
responsive families such as the HIN200s [22], are very different in
terms of copy number and genomic organization [7]. We therefore
asked whether either of the human genes most closely related at a
sequence level to Slfn4 (hSLFN12 and hSLFN12like) were regulated
in human macrophages. hSLFN12like mRNA was barely detect-
able in primary human monocyte-derived macrophages (HMDM)
and was not consistently regulated by LPS in HMDM from
different donors (data not shown). In contrast, hSLFN12 mRNA
expression was up-regulated by LPS in HMDM from multiple
independent donors, with maximal induction at the latest time
point examined (,4–5 fold, Figure 3C). This finding suggests that
hSLFN12 could be a functional ortholog of mSlfn4.
Slfn4 mRNA is down-regulated during macrophage
differentiation
Type I IFN inhibits CSF-1-mediated proliferation of macro-
phages in vitro [23], but it is essential for normal myelopoiesis in vivo
[4]. In the light of the observation that the Slfn2 gene mutation
alters monocyte maturation [13], as well as the fact that Slfn4 is a
type I IFN-dependent gene in BMM, we examined Slfn4 mRNA
levels during CSF-1-mediated differentiation of bone marrow
progenitors into BMM. Slfn4 mRNA was highly expressed in
unstimulated bone marrow cells (day 0), but rapidly declined in
response to CSF-1 (Figure 3D). As expected, csf1r mRNA levels
showed an opposing profile, with mRNA levels increasing during
differentiation (Figure 3E). Consistent with our hypothesis that
hSLFN12 may be a functional ortholog of mSlfn4, expression
profiling data on biogps.gnf.org revealed that hSLFN12 mRNA is
more highly expressed in CD33-positive myeloid progenitors than
in CD14
+ monocytes.
Figure 2. Putative regulatory elements within the Slfn4 promoter. The Slfn4 proximal promoter is a TATA-containing promoter with putative
binding sites for STAT1, IRF family members, PU.1 and AP1. The TSS, designated +1, is marked with an arrow.
doi:10.1371/journal.pone.0015723.g002
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PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e15723Figure 3. Slfn4 mRNA is induced via autocrine type I IFN and is down-regulated during macrophage differentiation. (A) BMM were
stimulated with LPS (10 ng/ml), dsRNA Poly(I:C) (30 mg/ml), Imiquimod (15 mg/ml), Zymosan (150 mg/ml), synthetic phosphorothioate CpG
oligonucleotide 1668S (0.3 mM) and non-stimulatory control oligonucleotide 1668S-GC (0.3 mM), Pam3Cys (15 ng/ml), or IFN-c (500 pg/ml) over a 24h
time course. The data, displayed as fold induction relative to control (0h), are combined from two independent experiments (mean + range). (B) BMM
from IFNAR-1
2/2 and wild type mice were stimulated with LPS over a time course. The data are combined from two independent experiments (mean
+ range). C) HMDM were stimulated with LPS over a time course (0h no treatment control, 2h, 6h, 24h). The data are combined from eight
independent donors (mean + SEM). (D, E) Bone marrow progenitors were differentiated into BMM in the presence of CSF-1 over a 6-day time course.
Data are combined from three independent experiments (mean + SEM). Slfn4 (A–D) and csf1r (E) mRNA expression was determined using quantitative
real-time PCR. * P,0.05 compared to 0h or day 0 control; ** P,0.01 compared to 0h or day 0 control; *** P,0.001 compared to 0h or day 0 control.
doi:10.1371/journal.pone.0015723.g003
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phagocyte system in vivo dysregulates myelopoiesis
The Slfn gene family is expanded in mice [7], and non-helicase-
containing Slfn family members showed a similar pattern of
regulation in macrophages (Figure 1). We therefore hypothesized
that related family members may render Slfn4 functionally
redundant and that genetic deletion of this gene may not
necessarily reveal a phenotype. Therefore, to determine the
significance of down-modulation of Slfn4 during macrophage
differentiation, and/or its induction by LPS and IFN, we
expressed the gene constitutively in myeloid cells. To do so, we
employed a novel binary system, the Csf1r-GAL4VP16/UAS-
ECFP mice (MacBlue mice) [24]. In MacBlue mice, the myeloid-
restricted csf1r promoter drives expression of the GAL4-VP16
transcriptional activator, which in turn binds to the UAS repeats
upstream of ECFP to drive expression of ECFP in myeloid cells
(Figure 4A). MacBlue transgenic mice can also be utilised for
macrophage-specific over-expression of UAS-containing GAL4-
dependent transgenes [24]. The csf1r promoter used in the
MacBlue mice has an internal deletion that abolishes expression in
placental trophoblasts and osteoclasts, and reduces expression in
mature macrophages and granulocytes [25]. We generated four
independent UAS-Slfn4-V5 founder lines to mate with the
MacBlue mice to generate double transgenics (MacBlue/UAS-
Slfn4-V5 transgenic mouse, Figure 4A). BMM from double-
transgenics from the four UAS-Slfn4-V5 founder lines expressed 2,
4, 5 and 20 fold higher levels of Slfn4 mRNA than BMM from
MacBlue littermate controls (Figure 4B), effectively providing an
allelic series. The levels of Slfn4 mRNA were already high in bone
marrow cells, and were only moderately elevated in bone marrow
from MacBlue/UAS-Slfn4-V5 mice as compared to littermate
controls (UAS-Slfn4-V5 and MacBlue mice) (Figure 4B). Despite
the transgene expression, Slfn4 mRNA expression was still down-
regulated in BMM as compared to bone marrow cells in all of the
lines (Figure 4B), as we observed previously (Figure 3D). Thus, the
levels of Slfn4 mRNA over-expression remain within a physiolog-
ical range in the transgenic animals. In effect, the transgenes
generated the desired outcome of maintaining Slfn4 mRNA in
macrophages at similar levels to those present in their progenitors
(Figure 4B). It should be noted that these data are presented as
expression relative to the bone marrow cells from littermate
controls for each line, so that the general expression patterns
across the different transgenic lines can be compared. The actual
levels of Slfn4 mRNA expression did vary between the different
lines. Figure 4C shows that Slfn4 mRNA levels in BMM from
founder F4 were particularly elevated as compared to the other
three lines.
Decreased monocyte and elicited macrophage numbers
in Slfn4 over-expressing mice
To determine whether the sustained expression of Slfn4 has any
impact on myelopoiesis, peripheral blood leukocytes, thioglycol-
late-elicited peritoneal macrophages (TEPM), and bone marrow
were isolated and immunostained for the surface markers CSF1R
and F4/80 (monocyte/macrophage markers), Ly-6G (granulocyte
marker) or B220/CD45R (B cell marker) (Table 1). There was no
significant difference in the percentage of CSF1R, F4/80, B220/
CD45R or Ly-6G expressing cells in bone marrow from
MacBlue/UAS-Slfn4-V5 mice compared to littermate controls.
However, the percentage of CSF1R, F4/80, and ECFP expressing
cells (monocytes) was approximately 50% reduced in peripheral
blood from MacBlue/UAS-Slfn4-V5 mice, whilst the number of
Ly-6G positive cells (granulocytes) was unaffected. Reduced
monocyte numbers were observed in independent Slfn4 transgenic
lines, indicating that the phenotype was unlikely to arise from
insertional effects of the transgene. For the transgenic line with the
highest level of Slfn4 expression (Figure 4C), we also monitored
recruitment of inflammatory macrophages to the peritoneal cavity.
A statistically significant reduction in CSF1R, F4/80, and ECFP
expressing cells was observed in TEPM from MacBlue/UAS-
Slfn4-V5 mice, as compared to littermate controls (Table 1).
Furthermore, thioglycollate-elicited peritoneal exudates from Slfn4
transgenic mice contained 2–3 fold less cells than littermate
controls, and most of these cells were granulocytic in appearance
(data not shown). These findings suggest that ectopic expression of
Slfn4 in csf1r-positive cells dysregulates myelopoiesis, and conse-
quently, the recruitment of inflammatory macrophages.
Slfn4 over-expression did not alter bone marrow
proliferation or cell viability
A steady-state reduction in blood monocytes could result from a
decrease in monocyte production in the marrow, or a reduction in
circulating half-life. As noted in the introduction, other Slfn family
members when over-expressed inhibit growth. To determine
whether there was any impact of Slfn4 on either the frequency or
proliferation of hematopoietic progenitor cells, CFU assays were
performed with bone marrow from MacBlue/UAS-Slfn4-V5 mice
and littermate controls. Bone marrow progenitor cells were
cultured in vitro in semisolid methylcellulose medium to examine
CFU-GM. Bone marrow progenitor cells were also cultured in the
presence of CSF-1 to assess the effect of Slfn4 over-expression on
high proliferative potential colony-forming cells, which produce
very large colonies (diameter .0.5 mm) when cultured with IL-3
plus CSF-1 due to an increase in CSF-1R expression [26,27].
There was no significant difference in size (Figure 5A) or frequency
(Figure 5B) of CFU-GM and high proliferative potential colony-
forming cells from MacBlue/UAS-Slfn4-V5 bone marrow com-
pared to MacBlue bone marrow. This finding is not entirely
surprising given that the transgene does not greatly increase the
already high expression of Slfn4 in bone marrow cells. We
therefore examined macrophage proliferation in liquid culture.
There was no impact of the MacBlue/UAS-Slfn4-V5 transgene on
the time course, or the ultimate yield of viable cells, in liquid
cultures of bone marrow cells in CSF-1 (Figure 5C). These data
suggest that some factor required for the in vivo Slfn4 phenotype is
not present in the in vitro conditions used here.
Slfn4 over-expressing animals display splenomegaly
MacBlue/UAS-Slfn4-V5 mice with the highest level of trans-
gene expression (20 fold over control, F4; Figure 4C) displayed
splenomegaly; spleens were diffusively and symmetrically enlarged
(Figure 6A), and there was a 3 to 4 fold increase in splenic weight
relative to the total body weight compared to littermate controls
(Figure 6B). There was also a trend towards an increase in liver
weight, but no difference in weight or macroscopic appearance of
other tissues examined including thymus, heart, lung, and kidney
(Figure 6B). Histological examination of organs from MacBlue/
UAS-Slfn4-V5 mice revealed an increase in neutrophils in the liver
(Figure 7A, arrowheads), as well as an increase in neutrophils and
megakaryocytes in the spleens (Figure 7B, arrows). The clear
definition of red and white pulp in the spleen was also lost in these
mice (Figure 7B), whilst the cellularity or morphology of other
tissues from Slfn4 over-expressing animals was not altered (data not
shown). Staining of liver and spleen sections with the macrophage
marker F4/80 also revealed an increase of macrophages,
particularly in liver, which often surrounded aggregates of
neutrophils (Figure 7A, arrow).
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PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e15723Figure 4. Macrophage-specific expression of the UAS-Slfn4-V5 transgene. (A) Elements of the UAS-Slfn4-V5 transgene include six UAS, a
kozak sequence, and the open reading frame of Slfn4 followed by a V5-tag. Upon crossing of the UAS-Slfn4-V5 mouse with the MacBlue mouse, the
offspring (MacBlue/UAS-Slfn4-V5 mice) contain the GAL4-expressing module, the GAL4-reporting module, and the UAS-Slfn4-V5 transgene. GAL4/
VP16 protein binding to both the UAS induces the expression of ECFP and Slfn4-V5 specifically in cells of the myeloid lineage. (B and C) RNA from
bone marrow (BM) or BMM from the offspring of four UAS-Slfn4-V5 founder lines (F1–F4) was extracted and cDNA was prepared. Slfn4 mRNA levels
relative to hprt were determined by quantitative real-time PCR. Data are combined from at least two independent experiments (mean + range) and
are presented as expression relative to BM controls to enable normalization across different the transgenic lines (B), or as expression relative to hprt
(no normalization across the transgenic lines) (C).
doi:10.1371/journal.pone.0015723.g004
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disaggregated the spleen and stained for myeloid markers. The
MacBlue marker (ECFP) itself provides a marker of myeloid
maturation because of the promoter deletion, which restricts
expression to mature macrophages [24,25]. There was an ,3 fold
increase in the percentage of cells expressing the monocyte/
macrophage-specific F4/80 marker, and an ,10 fold increase in
the percentage of cells expressing the granulocyte-specific Ly-6G
marker in the enlarged spleens from MacBlue/UAS-Slfn4-V5 mice
compared to littermate control mice (Figure 8). Correspondingly,
the percentage of B220/CD45R-expressing B cells and CD3e-
expressing T cells were both decreased (,3–4 fold) (Figure 8).
Interestingly, the percentages of splenic macrophages expressing
both F4/80 and ECFP, and granulocytes expressing both Ly6G
and ECFP, were increased only marginally. One possibility is that
Slfn4-positive progenitors are selected against, with concomitant
expansion of Slfn4-negative progenitors in the spleen. In support of
this idea, we did not detect significant numbers of CSF-1R
+
ECFP
2 cells in the spleen (data not shown), suggesting that the
expanded myeloid ECFP
2 cells in the spleen did not express Slfn4.
In summary, a threshold level of ectopic Slfn4 expression appears
to generate a form of myelodysplasia, because the phenotype was
not observed in lines expressing lower levels of Slfn4. Given that
the splenomegaly phenotype was apparent in only one line
however, we cannot completely exclude the possibility that
insertional effects generate this phenotype.
Discussion
The limited studies thus far performed on the Slfn genes suggest
a role in cell growth and differentiation. Indeed, very recent
studies have implicated Slfn2 and Slfn3 in the differentiation of
monocytes [13] and the intestinal epithelium [28,29] respectively.
We showed that Slfn4 mRNA expression was substantially reduced
during CSF-1-mediated macrophage differentiation (Figure 3D),
and that numbers of monocytes and recruited inflammatory
macrophages were reduced in mice constitutively expressing Slfn4
in the myeloid lineage (Table 1). The most obvious interpretation
of these data is that Slfn4 is a negative regulator of monocytopoi-
esis. We also observed increased numbers of macrophages in the
livers and spleens of Slfn4 transgenic mice (Figure 7, 8). Given this
observation, an alternative explanation is that enforced Slfn4
expression does not affect monocyte production, but causes
dysregulated monocyte trafficking, which results in increased
macrophage numbers in these organs. We cannot discount this
possibility, but several lines of evidence suggest that this phenotype
is more likely to relate to disrupted myelopoiesis. Firstly, we
observed increased numbers of granulocytes and megakaryocytes,
not just macrophages, in the spleens of Slfn4 transgenic mice
(Figure 7, 8). Secondly, the normal splenic architecture was
disrupted (Figure 7). These are both features of extramedullary
haematopoiesis, typically associated with a defect in normal
haematopoiesis. Of note, the increased granulocyte and macro-
phage populations in the spleens of Slfn4 transgenic mice were
predominantly negative for the UAS-dependent CFP transgene
(Figure 8). Therefore, if there is defective monocyte trafficking, it is
unlikely to result from cell-autonomous effects of Slfn4-expressing
monocytes, since this transgene is also UAS-dependent. A more
likely explanation is that, in the spleens of Slfn4 transgenic mice,
there is a preferential expansion of a sub-set of myeloid progenitors
that do not ectopically express Slfn4. This is also supported by our
observation that it was essentially only the ECFP
+ cells that were
CSF-1R
+ in the spleens of these mice (data not shown), again
suggesting that the expanded myeloid population do not express
Slfn4. Together with our data on gene regulation during
macrophage differentiation (Figure 3D), the phenotypes of the
Slfn4 transgenic mice (Table 1, Figure 7, Figure 8) lead us to
hypothesize that down-regulation of Slfn4 expression is a necessary
step required for normal differentiation along the monocyte/
macrophage lineage. In this scenario, enforced Slfn4 expression in
the myeloid lineage would disrupt monocytopoiesis. It should be
noted that only the line with the greatest level of Slfn4 expression
(Figure 4C) displayed the splenomegaly phenotype. We therefore
cannot completely exclude that this particular phenotype arises
from an insertional effect of the transgene, but this would seem
unlikely because the monocytopoiesis defect was apparent in
multiple independent lines, and because various Slfn family
members have been shown to regulate immune cell development
and/or survival. A more likely explanation is that a threshold level
of Slfn4 expression is required to reveal the more severe
splenomegaly phenotype.
The molecular mechanisms by which Slfn4 regulates monocyte/
macrophage development and/or function are unclear. When
expressed in HEK293T cells, helicase-containing Slfns were
present in the nucleus, whilst Slfn2 and Slfn4 (non-helicase-
containing Slfns) were exclusively cytoplasmic [30]. Similarly, we
found that Slfn4 was localized to the cytoplasm when ectopically
expressed in RAW264 mouse macrophages (WvZ, unpublished
data). Slfn family members all contain an AAA domain, which is
typically associated with protein oligomerization. One possibility is
that Slfn4 oligomerizes with Slfn2 since they are present in the
same cellular compartment [30]. In contrast to the down-
regulation of Slfn4 mRNA expression during macrophage
differentiation that we observed, expression of Slfn2 was up-
regulated during myeloid differentiation [30]. Consistent with this,
Slfn2 mRNA is expressed at elevated levels in mature macrophag-
Table 1. Decreased monocyte and elicited macrophage
numbers in Slfn4 over-expressing mice.
UAS-Slfn4-V5 MacBlue MacBlue/UAS-Slfn4-V5
BM (%)
CSF1R 10.162.5 10.962.8 11.363.5
F4/80 20.564.9 20.264.1 20.664.8
Ly-6G 40.269.7 36.5610.4 54.064.8
B220 (CD45R) 23.762.4 21.160.8 17.960.6
ECFP - 12.061.7 11.160.4
PBL (%)
CSF1R 9.560.1 8.261.8 2.861.5*
F4/80 9.760.2 10.161.7 4.361.0*
Ly-6G 36.860.6 35.264.7 33.860.9
ECFP - 11.762.2 5.160.9*
TEPM (%)
CSF1R 56.362.9 49.862.1 22.863.5 **
F4/80 59.964.4 43.962.8 20.964.3 *
ECFP - 44.260.9 28.862.8 **
BM, bone marrow; PBL, peripheral blood leukocytes; TEPM, thioglycollate-
elicited peritoneal macrophages. FACS data are combined from at least three
independent experiments. Data represent mean 6 SEM. For BM and PBL, data
were collected from two independent transgenic lines and littermate controls.
For TEPM, data were generated from the transgenic line with the highest





PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e15723Figure 5. Slfn4 over-expression did not alter bone marrow proliferation or cell viability. Bone marrow cells from MacBlue/UAS-Slfn4-V5
mice and littermate controls were cultured in semisolid methylcellulose medium in the presence (+) or absence (2) of CSF-1. The size (A) and
frequency (B) of colonies were examined on day 14. Data are combined from six independent experiments and are displayed as mean + SEM. (C) Bone
marrow cells from MacBlue/UAS-Slfn4-V5 mice and littermate controls were cultured in the presence of CSF-1 over a 7-day time course and cell
survival was measured on each day by MTT assay. Data are combined from three independent experiments and are displayed as mean 6 SEM.
doi:10.1371/journal.pone.0015723.g005
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regulatory role of Slfn4 in myelopoiesis that we propose, functional
Slfn2 was actually required for monocyte and T cell maturation
[13]. Hence, one possibility is that Slfn4 interacts with Slfn2, and
inhibits its function. In this setting, down-regulation of Slfn4 gene
expression would permit terminal macrophage differentiation by
removing the block on Slfn2 action. Whatever the case, our
understanding of the mechanisms by which Slfn4 and other
members of the family regulate monocyte/macrophage function is
hindered by the current lack of knowledge of Slfn functions at the
molecular level, and by the fact that AAA domain-containing
proteins have diverse roles in a multitude of biological processes.
Phylogenetic analysis of the Slfn genes indicated that the Slfn
gene region, located in an otherwise conserved human-mouse
interval, is evolving rapidly, possibly in response to selective
pressure related to their function in the immune response [7]. It
therefore remains an open question as to how conserved the
biology of Slfn genes is between humans and mice. Nonetheless,
the findings that LPS also up-regulated the mRNA expression of
hSLFN12 (Figure 3C), but not hSLFN12like (data not shown) in
HMDM, and that hSLFN12 mRNA was elevated in CD33-
positive myeloid progenitors compared to monocytes (biogps.gn-
f.org), indicates that mSlfn4 and hSLFN12 show similar regulation.
We therefore speculate that these 2 genes may also have conserved
functions in mice and humans respectively; future functional
studies on hSLFN12 may reveal roles in human macrophage
differentiation. For example, it is possible that the myelodysplastic
syndrome associated with copy number gains at Chr 17q12 [31]
relates to elevated hSLFN12 expression and function, since this
gene is located in this region.
In addition to regulating monocyte/macrophage development,
Slfn4 is likely to have some role in regulating macrophage
activation, given the effect of TLR3 and TLR4 agonists on Slfn4
mRNA expression. TLR-inducible expression involves the auto-
crine, type I IFN-dependent pathway, but there was some residual
induction in IFNAR-1
2/2 macrophages (Figure 3B), and by
agonists that act in a strictly MyD88-dependent manner
(Figure 3A). The role of type I IFN in the induction of Slfn4 is
consistent with the presence of appropriate response elements in
the promoter (Figure 2). A major function of IFNs is to protect
cells against viral infection by inducing a suite of genes involved in
host defence [32]. As a type I IFN-inducible gene, Slfn4 may play
some role in responses to viral infections. Consistent with this,
Slfn4 was induced in macrophages in response to adenovirus
infection (AI, unpublished data), and microarray data published by
others reported up-regulation of Slfn4 mRNA in BMM upon
infection with Sendai virus [33] and in the lungs of influenza A/
PR/8/34 virus infected mice [34]. Another link between Slfns and
responses to viral infections is suggested by the similarity between
these genes and the right inverted terminal repeat of several
orthopoxviruses [5,35]. Somewhat surprisingly, Slfnlike protein 176
from Camelpox strain CMS apparently reduces virulence, because
mice infected with recombinant vaccinia and variola viruses
expressing v-Slfn recovered sooner than mice infected with non-
recombinant virus [35]. What functional role Slfn4 has in anti-
viral responses remains to be determined. Unfortunately, we were
not able to assess the impact of the Slfn4 over-expression on host
defence because of the myelodysplastic phenotype of Slfn4
transgenic mice. This would render pathogen challenge experi-
ments uninterpretable. Furthermore, given that our in vitro
experiments assessing macrophage differentiation did not reveal
a phenotype despite the fact that Slfn4 regulated monocytopoiesis
in vivo, a yet to be identified in vivo factor may be required for Slfn4
function in vitro. Consistent with this, expression profiling of LPS-
activated Slfn4 over-expressing macrophages versus controls did
not reveal any consistent effect of constitutive Slfn4 expression on
the TLR4 response (data not shown). Consequently, the role of
Slfn4 in responses to TLR agonists and pathogen challenge in this
in vitro setting may require the identification of such a factor.
LPS robustly induced all members of the Slfn family that were
examined (Figure 1A). Slfn1, Slfn2 and Slfn4, which all lack the C-
terminal helicase-like domain, were late LPS response genes in
mouse macrophages, whilst the induction of helicase-containing
Slfns (Slfn5, 8 and 9) peaked earlier and declined somewhat by 24 h
(Figure 1A). Many TLR-inducible genes that are induced with
delayed kinetics act as negative feedback regulators of TLR
signalling by inhibiting the function of related isoforms [36]. We
therefore speculate that Slfn5, 8 and 9 are induced by TLR
agonists to perform specific helicase-dependent functions, and the
subsequent induction of non-helicase-containing Slfns permits
feedback regulation to switch off the response. If this is true, then
the elevated expression of Slfn1, Slfn2 and Slfn4 in CIA disease
tissue (Figure 1B) may represent a host attempt to dampen
inflammation. Whatever the exact functions of the short Slfn
isoforms in rheumatoid arthritis and other inflammatory diseases,
our expression analysis data are consistent with microarray
analysis from two other murine models of arthritis, human T-
cell leukemia virus type I transgenic mice and interleukin-1
receptor antagonist knockout mice [37].
In summary, we have shown that Slfn4 mRNA expression is
dynamically regulated during macrophage activation and differ-
Figure 6. Slfn4 over-expression caused splenomegaly. (A)
Macroscopic appearance of spleens from Slfn4 over-expressing mice
(right) and from MacBlue littermate controls (left). (B) Organ weights are
expressed as percentage of body weight. Data are combined from four
independent experiments and are displayed as mean + SEM.
doi:10.1371/journal.pone.0015723.g006
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transgene expression that we previously developed for CFP [24],
we have now demonstrated that this system also permits in vivo
analysis of gene function in macrophages. From the combined
data that we present here, we hypothesize that down-regulation of
Slfn4 expression during differentiation permits appropriate devel-
opment along the monocyte/macrophage lineage, that Slfn4 (as
well as other Slfn family members) are involved in macrophage
responses to pathogen challenge, and that hSLFN12 has similar
functions in human macrophages.
Materials and Methods
Ethics Statement
Prior to undertaking the studies described, approval for all
experiments using mice was obtained from the University of
Queensland Animal Ethics Committee (Project numbers: IMB/
494/07 and IMB/867/08). Approval for all experiments using
primary human cells was obtained from the University of
Queensland Medical Research Ethics Committee (Project num-
bers: 2007000755 and 2009001051).
Cell Culture and Reagents
RAW264.7 macrophage-like cells, obtained from the American
Type Culture Collection (ATCC, Rockville, MD, USA), were
cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA)
supplemented with 5% FCS (JRH Biosciences Inc, Lenexa, Ks),
20 U/ml penicillin (Invitrogen, Carlsbad, CA), 20 mg/ml strepto-
mycin (Invitrogen, Carlsbad, CA), and 2 mM L-glutamine
(Invitrogen, Carlsbad, CA) (complete medium). BMM were
obtained by ex vivo differentiation of mouse bone marrow cells in
the presence of recombinant human CSF-1 as described previously
[38]. To generate TEPM, mice were administered 1 ml 10%
thioglycollate broth by i.p. injection. Cellular exudates were
collected 5 days later. Peripheral blood from mice was collected
by cardiac puncture in a heparin-coated syringe, and red blood cells
were lysed with Red blood Lysing buffer (Sigma-Aldrich, St. Louis,
MO, USA). Splenocytes were obtained by digestion of spleen with
Collagenase/Dispase and DNase (Roche, Mannheim, Germany),
and red blood cells were lysed with Geys solution. HMDM were
obtained by in vitro differentiation of CD14
+ monocytes [39].
Salmonella minnesota Re 595 LPS (Sigma-Aldrich, St Louis, MO) was
prepared as described previously [40]. Recombinant mouse IFN-c
was purchased from R&D systems (Minneapolis, MO, USA),
Pam3CysSerLys4 from Merck (Darmstadt, Germany), Zymosan
from Saccharomyces cerevisiae was from Sigma-Aldrich (St Louis, MO),
and R837 (Imiquimod) was purchased from InvivoGen (San Diego,
CA, USA). Phosphorothioate-modified oligodeoxynucleotides
(Geneworks, Adelaide) used were CpG DNA-activating oligonucle-
otide 1668S: 59-TCCATGACGTTCCTGATGCT-39 and the
corresponding control GpC oligonucleotide 1668S-GC: 59-TC-
CATGAGCTTCCTGATGCT-39.
Figure 7. Increased neutrophils and macrophages in the livers and spleens of MacBlue/UAS-Slfn4-V5 mice. (A) Hematoxylin and eosin
staining was performed on liver paraffin sections. Arrowheads indicate aggregates of neutrophils in the liver. Liver sections from MacBlue/UAS-Slfn4-
V5 and MacBlue littermate controls were also stained for F4/80 (brown). Arrows indicate F4/80 expressing cells surrounding aggregates of
neutrophils. (B) Hematoxylin and eosin staining was also performed on spleen paraffin sections. Arrows indicate clusters of megakaryocytes. Spleen
sections from MacBlue/UAS-Slfn4-V5 and MacBlue littermate controls were also stained for F4/80 (brown). Sections were examined using an Olympus
BX-51 microscope with a DP-70 digital camera and DP controller imaging software (Olympus). RP, red pulp; WP, white pulp.
doi:10.1371/journal.pone.0015723.g007
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DBA/1 mice were immunised with chicken type II collagen as
previously described [41], and each limb was allocated a clinical
score for arthritis, which was based on the following criteria;
0=normal; 1=light swelling; 2=extensive swelling and/or
redness of the footpad; 3=joint distortion and/or rigidity [42].
Figure 8. Increased macrophages and granulocytes in spleen from MacBlue/UAS-Slfn4-V5 mice. Splenocytes from MacBlue littermate
controls (A) and MacBlue/UAS-Slfn4-V5 mice (B) were stained for the cell surface markers F4/80 (macrophage), Ly-6G (granulocyte), B220 (CD45R, B
cell), and CD3e (T cell). The samples were analysed by FACS and quadrants were set based upon isotype control profiles. Data are representative of
two independent experiments.
doi:10.1371/journal.pone.0015723.g008
Table 2. Real-time PCR primers used in this study.
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reverse transcribed and subjected to quantitative real-time PCR.
Real-time PCR analysis of gene expression
RNA, prepared using Qiagen mini-kits (Qiagen, Valencia, CA),
was reverse transcribed to cDNA with Superscript III reverse
transcriptase (Invitrogen, Carlsbad, CA, USA). cDNA levels of all
genes and the internal control, hypoxanthine-guanine phosphor-
ibosyl transferase (hprt), were estimated by quantitative real-time
PCR using SYBR Green (Applied Biosystems, Foster City, CA),
gene specific primers, and an ABI Prism 7000 sequence detection
system (Applied Biosystems). Threshold cycle (Ct) values were
calculated from amplification plots and gene expression was
expressed relative to the control gene, hprt. The primers used to
detect expression of the corresponding genes are described in
Table 2.
Generation of transgenic mice
Murine Slfn4 cDNA was cloned into the pGene vector
(Invitrogen, Carlsbad, CA, USA). To generate the upstream
activating sequence (UAS)-Slfn4-V5 transgenic mouse line, this
construct was isolated from the plasmid backbone, gel purified,
and injected into pronuclei of F2BCB (C57BL/6JxCBA) zygotes
(performed by the Transgenic Animal Service of Queensland,
http://tasq.uq.edu.au). Offspring from three independent injec-
tions were screened for incorporation of the transgene by PCR
amplification of tail tip genomic DNA. Identified UAS-Slfn4-V5
founders were crossed with Csf1r-GAL4VP16/UAS-enhanced
cyan fluorescent protein (ECFP) mice [24], and the offspring
were screened for the presence of the UAS-Slfn4-V5 (f, 59-
GTGCATTGGAACGCGCATTCC-39;r ,5 9-ATCCATCTTC-
CTCGCTTGGCAT-39), Csf1r-GAL4VP16 (f, 59-TGGGCCT-
TCCGTGGCTTTGTTG-39;r ,5 9-GCGGCCGCTAGATCTC-
GAGCATATCTCGAC-39), and UAS-ECFP (f, 59-GTGCA-
TTGGAACGCGCATTCC-39;r ,5 9-GCTGAAGCACTGCA-
CGCCCC-39) transgenes by PCR amplification. Male and female
mice of a mixed background, between 6 and 9 weeks of age were
included in this study. Mouse colonies were maintained under
specific pathogen-free conditions at the Institute for Molecular
Bioscience, University of Queensland, Australia. This study was
carried out in strict accordance with the recommendations of the
relevant University of Queensland Animal Ethics Committee, and
all efforts were made to ameliorate suffering.
Organ weight and Histomorphology
Tissues from animals were harvested, and their weight and body
weight were recorded. Tissues were fixed in paraformaldehyde
and paraffin embedded. Sections were stained with eosin or an
antibody against F4/80 (Serotec, Oxford, UK) and counterstained
with Mayer’s haematoxylin as described previously [43].
Flow cytometry
Cells were washed in ice-cold 0.1% BSA, 0.1% NaN3 in PBS
and incubated with primary antibody for 30 min. Cells were then
washed (0.1% BSA, 0.1% NaN3 in PBS), incubated with
secondary antibody for 30 min, washed with PBS, and analysed
using a BD LSRII flow cytometer (BD Biosciences). AFS98, a
mAb directed against the murine CSF-1 receptor was obtained
from John Hamilton (University of Melbourne, Melbourne
Australia). Other antibodies used were directed against F4/80
(Serotec, Oxford, UK), Ly-6G (BD Pharmingen, San Diego, CA,
USA), B220 (CD45R) (BD Pharmingen, San Diego, CA, USA), or
CD3e (BD Pharmingen, San Diego, CA, USA). Secondary
antibodies conjugated to PE were purchased from Serotec
(Oxford, UK).
Colony-forming unit assay
CFU assays with bone marrow cells were performed using
MethoCult semisolid methylcellulose medium containing a
cytokine cocktail of Stem Cell Factor, IL-6, and IL-3 (StemCell
technologies, Vancouver, Canada) with or without 10
4 U/ml
CSF-1 according to manufacturer’s instructions. The frequency
and size of the colonies were assessed on day 14 using light
microscopy.
MTT Assay
MTT assays were conducted as previously described [38]. The
absorbance was read with a Powerwave XS plate reader (Bio-Tek,
Winooski, VT, USA).
Statistical analysis
When data from multiple independent experiments were
combined, the mean and SEM of the numeric data was calculated.
Data were analyzed by Student’s t test, where appropriate.
Comparisons of data sets yielding P values of greater than 0.05
were regarded as not statistically different.
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